Remote Symptom Monitoring and Management RESPONd in Cancer Care
Evaluating Effects on Patient Outcomes and Clinic Efficiency
Led by University of Calgary · Updated on 2026-04-30
1055
Participants Needed
4
Research Sites
17 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating whether a remote symptom monitoring and management program called RESPONd can improve patient outcomes and increase efficiency in cancer care. This program allows cancer patients to complete electronic symptom questionnaires from home between visits and receive personalized advice from a study nurse. The study also aims to understand how this electronic symptom tracking affects clinic operations and resource use across various cancer centers.
Participants will report their symptoms regularly using electronic questionnaires, which will be reviewed by study nurses who provide timely support based on symptom complexity. The program includes team planning sessions before clinics to help identify patients who may benefit from virtual or nurse-led care. The study is conducted over 1.5 years in six different clinics, comparing this new approach with usual care.
During the study, participants will complete quality of life and health assessments at the start, 3 months, and 6 months. Researchers will also track emergency visits, hospital admissions, and economic outcomes over about 18 months. Patients will provide feedback about their experience, and staff perspectives will be collected quarterly. The study combines quantitative data with interviews to better understand patient experiences and factors affecting implementation.
CONDITIONS
Brief Title
Implementing REmote SymPtom mOnitoring and maNagement (RESPONd)
Research Team
C
Chizoba Anyimukwu, MPH, DrPH
B
Benedicta Asante, RSW, MSW
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Receiving care in one of the participating clinics
Able to sign up for MyAHS Connect and provide consent
Have access to a digital device at home
Able to complete electronic symptom questionnaires without clinic team support weekly (active treatment) or monthly (follow-up)
Have regular access to a telephone for study nurse contact
You will not qualify if you...
Cognitive disabilities or inability to reliably report symptoms independently
Not residing in Alberta (government-issued ID required for MyAHS Connect)
Lack of regular access to a telephone
Do not speak English or lack an English-speaking helper to assist with the electronic questionnaires
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Remote Symptom Monitoring and Management
Duration - Up to 18 months
Participants will complete electronic patient-reported outcomes (PROs) questionnaires digitally to report their symptoms. A study nurse will monitor these symptom reports between clinic visits and contact participants to provide personalized symptom support and management.
Weekly or monthly electronic symptom questionnaires depending on treatment phase
Clinic Team Huddle
Duration - Up to 18 months
Clinic teams will hold weekly planning sessions to review electronic PROs data and coordinate care based on participants' symptom complexity, potentially adjusting care routes such as virtual care or nurse-led clinics.
Weekly team huddles (no participant visits required)
Participant Assessments
Duration - 6 months
Participants will complete quality of life and self-rated health assessments at baseline, 3 months, and 6 months to measure outcomes related to symptom management and overall well-being.
3 visits (baseline, 3 months, and 6 months)
Long-term Monitoring
Duration - Approximately 18 months
Participants' health care utilization, including emergency department visits and hospital admissions, as well as economic outcomes, will be monitored for an average of 18 months to evaluate the impact of remote symptom management.
Ongoing remote monitoring with no additional visits required
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Similar Trials
Phase III Study of Oral Zotiraciclib for Recurrent Malignant Gliomas with IDH1 or IDH2 Mutations
Study of 18F-FAPI-04 PETCT and PETMR Scans for Detecting and Monitoring Various Cancers
18F-grazy-02 PETCT Imaging to Monitor Immunotherapy Responses in Adults with Lung Cancer or Melanoma
Study of 68Ga-NYM096 PETCT Imaging to Measure Tracer Uptake in Different Types of Cancer Including Primary and Metastatic Tumors
PET Imaging Using 68GaGa-Sa-DABI-4 to Detect Stimulator of Interferon Gene Expression in Adults with Cancer
Behavioral Intervention to Help Young LatinoHispanic Men with Cancer Manage Emotions and Life Goals
Prospective Clinical and Biological Database of Cancer Patients Starting Anticancer Immunotherapy
Tracking Immune-Related Side Effects Over Time
Phase I Trial Evaluating Safety and Dose of PA5 Intravenous Treatment for Adults With Advanced Solid Tumors
Online Platform for Sharing Cancer Patient Information
To Support Treatment Decisions and Accelerate Research
Study of a Decision Support Program for Older Adults 60 with Acute Myeloid Leukemia and Their Caregivers
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Patient-Reported Symptom Complexity and Acute Care Utilization Among Patients With Cancer: A Population-Based Study Using a Novel Symptom Complexity Algorithm and Observational Data.